Holdings
Hhlr Advisors, LTD.
As of Jun 30, 2026, Hhlr Advisors, LTD. reported 24 positions worth US$347M. Largest: Arrivent Biopharma, Inc., Marvell Technology, Inc. and Ke Holdings, Inc. Class A. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Arrivent Biopharma, Inc. | 3.93M | US$136M | held for review | Jun 30, 2026 |
| Marvell Technology, Inc. | 163K | US$48.5M | held for review | Jun 30, 2026 |
| Ke Holdings, Inc. Class A | 2.22M | US$32.2M | held for review | Jun 30, 2026 |
| Cytek Biosciences, Inc. | 6.66M | US$29.5M | held for review | Jun 30, 2026 |
| Alamar Biosciences, Inc. | 956K | US$25.9M | held for review | Jun 30, 2026 |
| Odyssey Therapeutics, Inc. | 832K | US$15.6M | held for review | Jun 30, 2026 |
| Contineum Therapeutics, Inc. | 669K | US$11M | held for review | Jun 30, 2026 |
| Maze Therapeutics, Inc. | 366K | US$10.9M | held for review | Jun 30, 2026 |
| Taiwan Semiconductor Manufacturing Co., Ltd. | 15,510 | US$7.41M | held for review | Jun 30, 2026 |
| Sagimet Biosciences Inc. - Series A | 725K | US$5.6M | held for review | Jun 30, 2026 |